⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42589 | 1.00 | — | — | |
| SCHEMBL2208297 | 1.00 | — | — | |
| SCHEMBL10894944 | 0.92 | SHBG (0.41) | — | |
| SCHEMBL5179627 | 0.92 | SHBG (0.41) | — | |
| SCHEMBL6756350 | 0.92 | SHBG (0.41) | — | |
| SCHEMBL10894956 | 0.92 | SHBG (0.41) | — | |
| SCHEMBL10894962 | 0.92 | SHBG (0.41) | — | |
| SCHEMBL6756349 | 0.92 | SHBG (0.41) | — | |
| SCHEMBL11033597 | 0.92 | SHBG (0.41) | — | |
| SCHEMBL4842068 | 0.89 | TSHR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023116866-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 杭州多域生物技术有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-11649212-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11247965-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020247496-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | ARCUS BIOSCIENCES, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20120028937-A1 | CYCLIC AMINE-1-CARBOXYLIC ACID ESTER DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-1841780-B1 | ANDROSTANE 17-ALPHA-CARBONATE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC AND INFLAMMATORY CONDITIONS | GLAXO GROUP LTD (GB) | 2011-07-27 | — | — | EP | disclosed |
| EP-2277861-A1 | CYCLIC AMINE-1-CARBOXYLIC ACID ESTER DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-7759342-B2 | Methods of treatment and prevention using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7579335-B2 | Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-20080249077-A1 | 17.Beta.-Fluoromethoxycarbonyl-Androst-4-En-3-One Compounds With a 17.Alpha.-Carbonate Sustituent | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| US-20080182831-A1 | Androstane 17-Alpha Carbonate Derivatives for Use in the Treatment of Allergic and Inflammatory Conditions | GLAXO GROUP LIMITED | 2008-07-31 | — | — | US | disclosed |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC | 2008-01-24 | — | — | US | disclosed |
| US-6534542-B2 | For alleviating chronic pain and allodynia and have no or only minimal cardivascular and/or sedatory activity | ALLERGEN SALES, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020161051-A1 | (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors | ALLERGAN SALES, INC. | 2002-10-31 | — | — | US | disclosed |